For instance, in 2016, a clinical study was conducted using 14 in 15 patients with glioma to enable the detection of CXCR4, and the imaging results were compared with that of O-(2-18F-fluoroethyl)-L-tyrosine ([18F]FET)-PET [136]. The gene discussed is CXCR4; the disease is central nervous system cancer.